AN2 Therapeutics, Inc. financial data

Symbol
ANTX on Nasdaq
Location
Menlo Park, CA
Fiscal year end
31 December
Latest financial report
10-Q - Q3 2025 - 12 Nov 2025

Key Ratios

Label TTM Value / Value Unit Change %
Debt-to-equity 11% % 6%
Return On Equity -48% % 17%
Return On Assets -43% % 18%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 27,402,024 shares -8.3%
Common Stock, Shares, Outstanding 27,371,154 shares -8.4%
Entity Public Float $41,131,046 USD -62%
Weighted Average Number of Shares Outstanding, Basic 30,276,230 shares 1.5%
Weighted Average Number of Shares Outstanding, Diluted 30,276,230 shares 1.5%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense $23,287,000 USD -53%
General and Administrative Expense $14,113,000 USD -4.3%
Operating Income (Loss) $37,391,000 USD 44%
Net Income (Loss) Attributable to Parent $33,986,000 USD 44%
Earnings Per Share, Basic -1 USD/shares 43%
Earnings Per Share, Diluted -1 USD/shares 43%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value $18,003,000 USD -46%
Assets, Current $64,016,000 USD -34%
Other Assets, Noncurrent $0 USD
Assets $67,235,000 USD -31%
Accounts Payable, Current $2,226,000 USD 30%
Employee-related Liabilities, Current $1,744,000 USD -17%
Accrued Liabilities, Current $2,705,000 USD -45%
Liabilities, Current $10,017,000 USD -32%
Liabilities $6,858,000 USD -32%
Accumulated Other Comprehensive Income (Loss), Net of Tax $64,000 USD -43%
Retained Earnings (Accumulated Deficit) $232,240,000 USD -17%
Stockholders' Equity Attributable to Parent $60,377,000 USD -31%
Liabilities and Equity $67,235,000 USD -31%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities $10,624,000 USD 40%
Net Cash Provided by (Used in) Financing Activities $65,000,000 USD 18525%
Net Cash Provided by (Used in) Investing Activities $9,193,000 USD -65%
Common Stock, Shares Authorized 500,000,000 shares 0%
Common Stock, Shares, Issued 27,371,154 shares -8.4%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect $1,366,000 USD -115%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $18,003,000 USD -46%
Deferred Tax Assets, Valuation Allowance $58,107,000 USD 39%
Deferred Tax Assets, Gross $58,107,000 USD 39%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent $34,034,000 USD 44%
Deferred Tax Assets, Operating Loss Carryforwards $28,682,000 USD 38%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 10,000,000 shares 0%
Unrecognized Tax Benefits $2,083,000 USD 43%
Additional Paid in Capital $292,553,000 USD 2.4%
Preferred Stock, Shares Outstanding 0 shares
Share-based Payment Arrangement, Expense $6,626,000 USD -25%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%